457 related articles for article (PubMed ID: 17883283)
1. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
2. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
3. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
6. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cai P; Tang X; Qin W; Ji L; Li Z
Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
[TBL] [Abstract][Full Text] [Related]
7. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Cozzolino M; Brandenburg V
Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
10. Calcimimetics versus vitamin D: what are their relative roles?
Drüeke TB
Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
12. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
[TBL] [Abstract][Full Text] [Related]
15. Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Cozzolino M; Galassi A; Pasho S; Fallabrino G; Gallieni M; Brancaccio D
Contrib Nephrol; 2008; 161():234-239. PubMed ID: 18451682
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
[TBL] [Abstract][Full Text] [Related]
17. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
Toussaint ND; Damasiewicz MJ
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
[TBL] [Abstract][Full Text] [Related]
18. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
19. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
Sprague SM; Coyne D
Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
